SCHEMBL146470

SCHEMBL146470

Oc1ccc2cc(SSc3ccc4cc(O)ccc4c3)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 1.00
ALOX15 P16050 1/20 1.00
TSHR P16473 1/20 1.00
HIF1A Q16665 1/20 1.00
HSD17B10 Q99714 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
CYP1A2 P05177 2/20 0.56
ESR2 Q92731 12/20 0.52
ESR1 P03372 11/20 0.52
ABL1 P00519 1/20 0.48
ABCB1 P08183 1/20 0.48
BCR P11274 1/20 0.48
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
HSD17B1 P14061 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B2 P37059 1/20 0.46
F12 P00748 1/20 0.45
NR1H2 P55055 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670854 1.00 CYP3A4 (1.00) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL30598779 1.00 CYP3A4 (1.00) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL11673478 0.84 CYP3A4 (0.73) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL69484 0.83 CYP1A2 (0.77) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL29364786 0.83 CYP1A2 (0.77) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL627219 0.83 CYP1A2 (0.77) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL592175 0.80 CYP3A4 (0.67) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL9702114 0.80 CYP3A4 (0.67) CYP3A4ALOX15TSHRHIF1AHSD17B10
Hydroquinone SCHEMBL6689552 0.80 ESR2 (0.74) CYP3A4ALOX15TSHRHIF1AHSD17B10
SCHEMBL27845395 0.80 CYP1A2 (0.72) CYP3A4ALOX15TSHRHIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119552517-A High-temperature-storage-resistant rubber composite modified asphalt and preparation method thereof 中石油克拉玛依石化有限责任公司 2025-03-04 CN claimed
CN-117964851-A 4D printable shape memory polymer material and printing method thereof 哈尔滨工业大学 2024-05-03 CN claimed
CN-117801219-A Phase-change energy storage material with self-healing capacity and preparation method thereof 四川大学 2024-04-02 CN claimed
CN-116144165-B Recoverable and repairable thermosetting polyurethane modified asphalt material and preparation method thereof 四川大学 2024-04-02 CN claimed
CN-117757401-A OCA optical cement, preparation method thereof and touch screen 广州鹿山新材料股份有限公司 2024-03-26 CN claimed
CN-115725018-B Thermosetting shape memory material and preparation method thereof 哈尔滨工业大学 2023-07-21 CN claimed
CN-115010872-B Preparation method of recyclable intrinsic flame-retardant waterborne polyurethane with interpenetrating crosslinked double-network structure 中国科学技术大学 2023-06-16 CN claimed
CN-116144165-A Recoverable and repairable thermosetting polyurethane modified asphalt material and preparation method thereof 四川大学 2023-05-23 CN claimed
CN-115725018-A Thermosetting shape memory material and preparation method thereof 哈尔滨工业大学 2023-03-03 CN claimed
EP-3331959-B1 ANIONIC CURABLE COMPOSITIONS DESIGNER MOLECULES INC (US) 2022-10-05 EP claimed
US-20070299154-A1 Mold compositions with high adhesion to metal substrates DESIGNER MOLECULES, INC. 2007-12-27 US claimed
US-20060127969-A1 Assays for trichomonal and other hydrolases QUIDEL CORPORATION (US) 2006-06-15 US claimed
US-7041469-B2 Assays for trichomonal and other hydrolases QUIDEL CORPORATION (US) 2006-05-09 US claimed
US-20050101771-A1 Used in clinical examinations and can precisely assay glycated proteins ASAHI KASEI PHARMA CORPORATION (JP) 2005-05-12 US claimed
EP-1422525-A1 Assays for Trichomonas vaginalis Quidel Corporation (US) 2004-05-26 EP claimed
US-20040072280-A1 Assays for trichomonal and other hydrolases QUIDEL CORPORATION (US) 2004-04-15 US claimed
WO-2003099852-A2 PEPTIDE DERIVATIZATION PROCESS RESTORAGEN INC. (US) 2003-12-04 WO claimed
EP-1362925-A1 COMPOSITIONS FOR ASSAYING GLYCOPROTEIN Asahi Kasei Kabushiki Kaisha (JP) 2003-11-19 EP claimed
US-6211389-B1 TREATING SPECIFICALLY DEFINED COMBINATIONS COMPRISING AN EPOXY RESIN STARTING MATERIAL AND OTHER COMPONENTS TO ORGANIC SOLVENT, A CROWN ETHER, AND A SUITABLE BASE TO CONDITIONS SUFFICIENT TO PRODUCE A TREATED EPOXY COMPOUND DEXTER CORPORATION 2001-04-03 US claimed
US-5342724-A Preparing polyester from diol and diacid wherein one of the monomers has disulfuide linkage, reacting polyester with unsaturated monomer to create addition polymer blocks linked by sulfide group from dislufide linkage EASTMAN KODAK COMPANY (US) 1994-08-30 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101771-A1 Used in clinical examinations and can precisely assay glycated proteins ALB, SERPINA6, DNPEP CYP3A4 2614/4885ALOX15 2301/4885TSHR 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.